Sartorius Stedim Biotech : S1 2020 solide et en ligne avec le trading update
>T2 en phase avec le récent trading update - Le CA T2 se monte à 447 M€, soit +21.7% et l’EBITDA atteint 135.6 M€. A fin juin, le CA se situe à 869 M€ (+22%) et l’EBITDA à 262 M€, soit 30.2% du CA (R&D contenue sur T2).Avec les dernières acquisitions, l’endettement net a progressé : 243.2 M€ (vs 110 M€ à fin 2019), soit un levier de 0.5x contre 0.3x en fin d’exercice 2019.Les Capex sont ponctuellement tombés à 5.8% du CA (effet du confinement) mais l’objecti...Sartorius Stedim Biotech is a provider of equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Co.'s solutions cover fermentation, filtration, purification, fluid management and lab technologies and membrane chromatography, including various conventional lab products to biopharmaceutical laboratories. Co.'s technologies, products and services are used to develop and manufacture medications and vaccines using biological methods. Co.'s products covers all upstream and downstream steps in the production of active pharmaceutical ingredients. It specializes in single-use products and offers technical consulting and services.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.